Levels of anti-insulin antibodies in diabetic retinopathy patients: an observational cross-sectional study.

Autor:	Mohammed BN; Department of Chemical Pathology, University of Ghana Medical School, Accra, Ghana., Ofori EK; Department of Chemical Pathology, University of Ghana Medical School, Accra, Ghana., Adekena CN; University of Ghana Medical Center, Accra, Ghana., Amponsah SK; Department of Medical Pharmacology, University of Ghana Medical School, Accra, Ghana., Asare-Anane H; Department of Chemical Pathology, University of Ghana Medical School, Accra, Ghana., Amanquah SD; Department of Chemical Pathology, University of Ghana Medical School, Accra, Ghana., Abdul-Rahman M; Department of Pathology, University of Ghana Medical School, Accra, Ghana., Amissah-Arthur KN; Eye Unit, Department of Surgery, University of Ghana Medical School, Accra, Ghana.
Jazyk:	angličtina
Zdroj:	Future science OA [Future Sci OA] 2024 May 15; Vol. 10 (1), pp. FSO982. Date of Electronic Publication: 2024 May 15 (Print Publication: 2024).
DOI:	10.2144/fsoa-2024-0002
Abstrakt:	Aim: This study evaluated the levels of anti-insulin antibodies (AIAs) and the influence of some antidiabetic medications on AIA in diabetes mellitus (DM) patients with retinopathy. Patient & methods: An observational cross-sectional study. Results: A lower titer of AIA IgG was observed in the diabetic retinopathy (DR) and DM-only study categories compared with the control group [DR = 86 (5-560), DM-only = 50 (5-500), versus control = 200 (7-565); p = 0.017]. Taking nifedipine and metformin were negatively correlated (r = -0.32, p = 0.04) with the levels of AIA IgE in the DR group. Conclusion: A decreased titer of circulating AIAs was observed in the DR study category, suggesting that AIA may not contribute to the pathogenesis of DR. Competing Interests: The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu